The stock of Caris Life Sciences shined in its Nasdaq debut on Wednesday, pricing its heavily-subscribed initial public offering at $21 per share and

The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite for biotech IPOs.

Caris Life Sciences raised $494.1 million in its Nasdaq initial public offering, the cancer diagnostic firm said on Tuesday, amid a rebound in the IPO market. Investors have shown renewed interest in U.